What is Denosumab?

Category: Prescription Drugs

Most popular types: Prolia Xgeva

false

Denosumab is a monoclonal antibody that is used for the treatment of osteoporosis, bone loss associated with certain cancer treatments, and the prevention of bone loss from cancer that has spread to the bone. It is given by an injection under the skin.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Osteoporosis 19 14
Bone metastases 8 5
Osteopenia 2 0
Giant cell tumor of the bone 1 1
Osteopetrosis 1 0

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 3
Moderate 2
Mild 4
None 11

Commonly reported side effects and conditions associated with Denosumab

Side effect Patients
Heartburn 2
Bone pain 1
Cyclic vomiting syndrome 1
Diarrhea 1
Fatigue 1
Generalized weakness (asthenia) 1

Show all 16 reported side effects

Dosages

Based on patients currently taking Denosumab

Dosage Patients
60 mg every 6 months 6
1 other every 6 months 1
70 mg every 6 months 1

Why patients stopped taking Denosumab

Multiple reasons could be selected

Reason Patients
Side effects too severe 1
See all 2 patients who've stopped taking Denosumab

Duration

Currently taking Denosumab

Duration Patients
1 - 6 months 2
6 months - 1 year 1
1 - 2 years 1
2 - 5 years 4

Stopped taking Denosumab

Duration Patients
Less than 1 month 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 17
Usually 2
Sometimes 0
Never taken as prescribed 1
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 2
A little hard to take 3
Not at all hard to take 15
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 1
$25-49 0
< $25 10
Not specified 9

What people switch to and from

Patients started taking Denosumab after stopping:

Treatment Patients
Risedronate (Actonel) 3
Alendronate (Fosamax) 1
Ibandronate (Boniva) 1
Raloxifene (Evista) 1
Zoledronic acid (Zometa) 1
Last updated:
There are no evaluations for Denosumab.